Alzheimer (AD) - a multifactorial neurodegenerative disease - a cohort study
DOI:
https://doi.org/10.47743/jemb-2024-210Keywords:
Alzheimer, Neurodegeneration, Multifactorial, Dementia, HereditaryAbstract
Situated within the broad spectrum of neurodegenerative disorders, Alzheimer's disease (AD) is known for its complexity, heterogeneity, multiple genetic mutations, epigenetic and biochemical modifications, and irreversible progression from early stages characterized by deficits in the ability to encode and store new information to subsequent progressive cognitive, functional, behavioral decline. Objective: The conducted study aimed to compile conclusive statistics, identify genetic factors, and correlate them with environmental ones, thus highlighting the importance of developing evaluation programs and early introduction of medication in order to decelerate the progression of neurodegenerative processes. Materials and methods: The analytical, observational, retrospective study was conducted on an extended cohort of 2277 patients admitted with chronic neurological diseases to the Neurology Department of "Dr. Iacob Czihac" Clinical Military Emergency Hospital Iași from January 1, 2022 to December 31, 2023. Among these, 219 patients were diagnosed with AD at various stages. Forty-three cases exhibiting genetic predisposition (19.63%) were selected and thoroughly analyzed based on medical records. Results: The study emphasizes the significant position of AD among chronic neurological diseases. Although the majority do not present hereditary antecedents (80.36%), predisposing conditions, environmental factors, stress, and the region of residence play fundamental roles in the disease's determinism. It is observed that individuals in the 60-70 age category (71.23%) from urban areas (63.01%), especially females (63.47%), have a higher probability of developing AD. Maternally transmitted Alzheimer's prevalence was 58.13%, while paternally inherited AD accounted for 32.55%, with only 4 cases having antecedents on both lines (9.30%). Conclusion: Unequivocally characterized by a vast etiology, AD is a multifactorial disorder resulting from the bilateral interaction and continuous corroboration of genetic and environmental factors.
References
Burns A, Byrne JE, Maurer K. 2002. Alzheimer’s disease. Lancet. 360:163–165. www.thelancet.com. DOI: https://doi.org/10.1016/S0140-6736(02)09420-5
Gao Y, Liu X. 2021. Secular trends in the incidence of and mortality due to Alzheimer’s disease and other forms of dementia in China From 1990 to 2019: An age-period-cohort study and joinpoint analysis. Front Aging Neurosci. 13(709156). doi:https://doi.org/10.3389/fnagi.2021.709156. DOI: https://doi.org/10.3389/fnagi.2021.709156
Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J. 2016. Why has therapy development for dementia failed in the last two decades. Alzheimers Dement . 12:60–64. doi:10.1016/j.jalz.2015.12.003. DOI: https://doi.org/10.1016/j.jalz.2015.12.003
GBD 2019 Dementia Forecasting Collaborators. 2019. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 7. doi:https://doi.org/10.1016/S2468-2667(21)00249-8. DOI: https://doi.org/10.1016/S2468-2667(21)00249-8
GBD 2019 Diseases and Injuries Collaborators. 2020. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet . 396:1204–1222. doi:10.1016/S0140-6736(20)30925-9. DOI: https://doi.org/10.1016/S0140-6736(20)30925-9
GBD 2019 Risk Factors Collaborators. 2020. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 369:1223–1249. doi:10.1016/S0140-6736(20)30752-2. DOI: https://doi.org/10.1016/S0140-6736(20)30752-2
Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, Kirabali T, Krolak-Salmon P, Rossini PM, Ferretti MT, et al. 2023. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimer’s and Dementia. 19(2):658–670. doi:10.1002/alz.12694. DOI: https://doi.org/10.1002/alz.12694
Hippius H, Neundörfer G. 2003. The discovery of Alzheimer’s disease. Dialogues Clin Neurosci. 5(1):101–108. doi:10.31887/dcns.2003.5.1/hhippius. DOI: https://doi.org/10.31887/DCNS.2003.5.1/hhippius
Li X, Feng x., Sun X, Hou N, Han F, Liu Y. 2022. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2019. Frontiers in Aging Neuroscience - Alzheimer’s Disease and Related Dementias. doi:10.3389/fnagi.2022.937486. http://ghdx. DOI: https://doi.org/10.3389/fnagi.2022.937486
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S. 2020. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet . 396:413–446. doi:10.1016/S0140-6736(20)30367-6. DOI: https://doi.org/10.1016/S0140-6736(20)30367-6
Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. 2015. Alzheimer’s disease. Nat Rev Dis Primers. 1. doi:10.1038/nrdp.2015.56. DOI: https://doi.org/10.1038/nrdp.2015.56
Maurer K, Volk S, Gerbaldo H. 1997. Auguste D and Alzheimer’s disease. THE LANCET. 349:1546–1549. DOI: https://doi.org/10.1016/S0140-6736(96)10203-8
Soria Lopez JA, González HM, Léger GC. 2019. Alzheimer’s disease. In: Handbook of Clinical Neurology. Vol. 167. Elsevier B.V. p. 231–255. DOI: https://doi.org/10.1016/B978-0-12-804766-8.00013-3
Stănescu A. 2015. Totul despre Alzheimer. Târgu Mureș: Farmamedia.
Szalontay AS. 2014. Actualități în boala Alzheimer. Iași: Editura Gr. T. Popa.
Szalontay AS, Chiriță V, Chiriță R. 2005. Boala Alzheimer - Management Clinico-Terapeutic. Iași: Editura U.M.F. “Gr.T.Popa” .
Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. 2019. Alzheimer’s disease: Pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 14:5541–5554. DOI: https://doi.org/10.2147/IJN.S200490
Downloads
Published
How to Cite
License
Copyright (c) 2024 Paula Denisa Saragea, Cristian Tudose
This work is licensed under a Creative Commons Attribution 4.0 International License.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. The journal allows readers to read, download, copy, distribute, print, search, link to the full texts or use the articles for any other lawful purpose.
The authors are the sole copyright owners of the published articles. The articles are distributed under the CC BY 4.0 license to the readers.
The readers are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.